News Breaks |
|
|
| March 4, 2013 |
| 09:04 EDT |  | REGN | Regeneron announces potential additional royalty stream related to EU approval
Regeneron announced that it will receive an additional potential royalty stream now that the European Commission has approved Novartis' llaris in the treatment of patients with acute gouty arthritis who suffer frequent attacks, and whose symptoms cannot or should not be managed with current treatment options. Ilaris is the first biologic approved in the European Union for symptomatic pain relief in a gouty arthritis indication, and is administered in a single, subcutaneous injection of 150 mg. Under a June 2009 agreement with Novartis, Regeneron receives royalties on worldwide sales of Ilaris. The overall royalty rate in the agreement starts at 4% and reaches 15% when annual sales exceed $1.5 billion. In 2012, Regeneron reported full year Ilaris royalties of $2.8 million. |
|
|
News For REGN From The Last 14 Days Check below for free stories on REGN the last two weeks. |
|
|
| May 17, 2013 |
| 10:07 EDT |  | REGN | On The Fly: Analyst Initiation Summary
 Subscribe for More Information |
|
| 07:16 EDT | | REGN | Regeneron initiated with a Neutral at UBS
Subscribe for More Information |
|
| 06:33 EDT |  | REGN | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| May 15, 2013 |
| 05:39 EDT | | REGN | Sanofi, Regeneron announce patient enrollment in two Phase 3 trials
Subscribe for More Information |
|
| May 14, 2013 |
| 07:34 EDT |  | REGN | Regeneron outlook positive, says RBC Capital
Subscribe for More Information |
|
| May 10, 2013 |
| 07:24 EDT | | REGN | Credit Suisse to host a conference
Subscribe for More Information |
|
| May 6, 2013 |
| 09:02 EDT | | REGN | Regeneron price target raised to $314 from $200 at Roth Capital
Subscribe for More Information |
|
|
|
|
|
